retatrutide phase 2 nejm 2023 obesity trial results SURPASS-2 (NEJM 2021) was the definitive head-to-head: tirzepatide vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type diabetes. All three tirzepatide doses produced superior HbA1c reductions Among participants 4 to 66

In the gastrointestinal tract, it causes increased intestinal permeability (leaky gut), cramping, and unpredictable food reactions

(2024.) BMJ

Overall, understanding and exploiting iron vulnerabilities within tumors and the TME could pave the way for new therapeutic strategies in cancer

"It's rare, but that's still a lot of people." Almost 5 out of every 1,000 patients experienced pancreatitis while taking semaglutide, while roughly 8 out of every 1,000 patients experienced that condition while taking liraglutide

Patients should not purchase weight loss medicines from unregulated online pharmacies, as counterfeit products pose serious health risks